Australia's most trusted
source of pharma news
Posted 30 July 2026 AM
The Health Department has made moves to quell a patient backlash over the upcoming withdrawal of AstraZeneca’s monthly Zoladex, with Ipsen stepping in to fill the gap.
AstraZeneca markets two strengths of Zoladex, an implant that delivers gonadotrophic releasing hormone agonist goserelin subcutaneously. Both the monthly 3.6 mg dose and the three-monthly 10.8 mg dose are listed on the PBS for prostate cancer, however, only the monthly option is TGA approved and listed on the PBS for endometriosis, breast cancer, and anticipated premature ovarian failure.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.